The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.

Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting ACE2 binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 entry through a hypothesized ?5?1 integrin-based mechanism, ...
and indicates that inhibiting the spike protein interaction with ?5?1 integrin (+/- ACE2), and the interaction between ?5?1 integrin and ACE2 using a novel molecule ATN-161 represents a promising approach to treat COVID-19.
JACC Basic Transl Sci
Date: Oct. 16, 2020
Download Curated Data For This Publication
222710
Switch View:
  • Interactions 1